• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
Sunday, June 15, 2025
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

VCU researchers test effectiveness of anti-opioid vaccine

Bioengineer by Bioengineer
December 6, 2018
in Health
Reading Time: 3 mins read
0
ADVERTISEMENT
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

IMAGE

Credit: VCU


Virginia Commonwealth University researchers are testing a vaccine against opioid abuse developed by the Scripps Research Institute in California. The vaccine is meant to block the effects of heroin and fentanyl in patients with opioid use disorder.

The methodology of VCU’s preclinical tests was recently featured in the journal Trends in Pharmacological Sciences. Lead author Matthew Banks, Pharm.D., Ph.D., associate professor in the Department of Pharmacology and Toxicology in the VCU School of Medicine, also explains the workings of the vaccine, and reviews the landscape of opioid immunotherapy research and hurdles to vaccine development. The article is part of the journal’s “Science & Society” series, which highlights pharmacological research efforts to combat the opioid crisis in language accessible to lay readers. Banks is currently in the process of submitting test results for peer review.

Researchers at the Minneapolis Medical Research Foundation and at Walter Reed Army Institute of Research are testing other anti-heroin and anti-oxycodone vaccines, Banks said.

“Anti-opioid vaccines represent one promising research area for opioid use disorder, including relapse and overdose because they are mechanistically different from current FDA-approved therapeutics such as naloxone, methadone and naltrexone, which target opioid receptors,” Banks writes. “The vaccines prompt an individual’s body to generate anti-opioid antibodies.”

The Scripps vaccine and other immunotherapies work by prompting the immune system to make antibodies that prevent drug molecules, such as heroin or fentanyl, from crossing the blood brain barrier into the central nervous system, blocking the effects of opioids.

“If a person injects heroin or fentanyl after they have been vaccinated, those antibodies are there to capture the drugs in the bloodstream, which should prevent people from getting high,” Banks said.

Similar to how the flu vaccine triggers immune response through exposure to flu viruses, opioid vaccines depend on some exposure to targeted opioid molecules to produce an immune response. Opioid molecules do not naturally produce an immune response, so they are attached to clinically available carrier proteins, such as the tetanus vaccine, to prompt the immune system to start producing antibodies. Scientists also added a chemical called an adjuvant to the vaccine to boost immune response.

Banks’ team is testing the efficacy of the vaccine and predicting how an immunized person might respond when faced with the choice of drug use or engaging with a nondrug reinforcer, such as work, friends or family.

“We develop the models to help move therapeutics along and then we collaborate with medicinal chemists who are generating new molecules to try to treat pain, and other collaborators developing novel therapeutics to treat opioid use disorder,” Banks said. “We are working with the Scripps Research institute to take those tools through the scientific process to determine if they are going to be effective.”

###

Media Contact
Leah Small
[email protected]
804-828-8355

Original Source

https://news.vcu.edu/article/VCU_Researchers_test_effectiveness

Related Journal Article

http://dx.doi.org/10.1016/j.tips.2018.08.001

News source: https://scienmag.com/

Tags: AddictionMedicine/HealthPharmaceutical ChemistryPharmaceutical SciencePharmaceutical SciencesPharmaceutical/Combinatorial ChemistryToxicology
Share12Tweet8Share2ShareShareShare2

Related Posts

Perivascular Fluid Diffusivity Predicts Early Parkinson’s Decline

Perivascular Fluid Diffusivity Predicts Early Parkinson’s Decline

June 14, 2025
blank

SP140–RESIST Pathway Controls Antiviral Immunity

June 11, 2025

Food-Sensitive Olfactory Circuit Triggers Anticipatory Satiety

June 11, 2025

Hippocampus Flexes Experience Coding with Rewards

June 11, 2025
Please login to join discussion

POPULAR NEWS

  • Green brake lights in the front could reduce accidents

    Study from TU Graz Reveals Front Brake Lights Could Drastically Diminish Road Accident Rates

    158 shares
    Share 63 Tweet 40
  • New Study Uncovers Unexpected Side Effects of High-Dose Radiation Therapy

    75 shares
    Share 30 Tweet 19
  • Pancreatic Cancer Vaccines Eradicate Disease in Preclinical Studies

    69 shares
    Share 28 Tweet 17
  • How Scientists Unraveled the Mystery Behind the Gigantic Size of Extinct Ground Sloths—and What Led to Their Demise

    65 shares
    Share 26 Tweet 16

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Magnetic Soft Millirobot Enables Simultaneous Locomotion, Sensing

Urban Form Shapes Compound Natural Risk: US Study

Perivascular Fluid Diffusivity Predicts Early Parkinson’s Decline

  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In
No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.